In recent decades, mammalian synthetic biology has shown that key principles of biological regulation can be rewritten to control gene expression and produce complex, yet orthogonal cellular behaviors. More recently, these core principles have been applied at the protein level, enhancing control over secreted protein components. The tools developed function entirely post-translationally, enabling synergistic strategies with engineerable regulation across multiple levels of the central dogma.
Using a platform known as Retained Endoplasmic Cleavable Secretion (RELEASE), the Gao Lab at Stanford University has demonstrated novel approaches that allow protein secretion systems to achieve the same tuning capabilities seen in gene circuits but focused solely on proteins. They envision future applications in re-wiring and regulating intercellular communication, with implications for cancer biology, immunology, and neuroscience.
These protein designs often require complex cloning strategies, including minimal sequence designs and repetitive motifs, which can be tedious to clone without modern DNA synthesis techniques.
Join us in this webinar case study to discover how using the right technology, their work can progress and iterate in ways that were previously unimaginable.
Ansa Biotechnologies was founded by scientists specifically to address the needs of customers like the Gao Lab. By developing a novel enzymatic synthesis method to contiguously synthesize 600 bp, the company can build nearly any sequence quickly, reliably and efficiently, even those rejected by other vendors.